Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Continued double-digit growth with PromactaⓇ/Revolade® and JakaviⓇ reflect strong execution PromactaⓇ/Revolade® USD m, % cc Ex-US US JakaviⓇ USD m, % cc +18% +16% 1.5bn 1.3bn 797 657 610 701 9M 2021 963 1.2bn 9M 2020 ■ Most used thrombopoietin receptor agonist with the broadest indication ■ +10% US NBRx share increase¹ driven by sustained efficacy, oral convenience and non-immunosuppressive profile ■ US indication expansion to include persistent ITP expected to fuel further growth MPN Myeloproliferative neoplasms ITP-Immune thrombocytopenia SAA - Severe aplastic anemia 9M 2020 9M 2021 ■ Standard-of-care JAK inhibitor in MPN with proven overall survival and quality of life benefit ◉ ☐ Strong double-digit growth across regions driven by earlier usage in myelofibrosis and polycythemia vera Preparing for launch of acute and chronic GVHD in 2022 GvHD Graft versus host disease 1. Data: IQVIA data, August Rolling 3-month data vs last year August 35 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation